[CMTM5 inhibits the tumor cell behavior of prostate cancer by downregulation of HER2].
To discover whether there is any other pathway than EGFR which has interaction with HER2 that makes a different down stream on cancer manners and whether CMTM5 plays a role in HER2 related tumor performance. HER2 and CMTM5 were detected on prostate cancer tissue chip using IHC. The protein levels of HER2, Cyclin D1 and CMTM5 were compared had with or without CMTM5 plasmid transfection on PC3 cell line to insure their relationship. The author demonstrated that the HER2 had been up regulated in prostate cancer epithelium while CMTM5 down regulated. Overexpression of CMTM5 in PC3 could lower the HER2 and Cyclin D1 protein level. The results suggest that in prostate cancer HER2 has a different partner in the signaling transduction other than EGFR as in a traditional pathway. CMTM5 may have a chance to be chosen as the next potential treatment bio-target of prostate cancer.